FDA Import Refusal SCS-9203563-4/11/1 — Boehringer Ingelheim Pharma GmbH & Co. KG
The FDA refused shipment SCS-9203563-4/11/1 from Boehringer Ingelheim Pharma GmbH & Co. KG (Germany) on Mar 17, 2020. The refused product falls under Drugs and Biologics — LINAGLIPTIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal details
- Date
- Mar 17, 2020
- Country
- Germany
- Product Category
- Drugs and Biologics
- Product Code
- 61PDA66 LINAGLIPTIN (ANTI-DIABETIC)
- Charges
- 75